Zestagen develops light chain mAbs against extracellular hsp90 (ehsp90), a subset of hsp90 that is purported to facilitate cancer cell motility, migration and metastasis. The antibody has documented proof-of-efficacy in in vitro assays as well as in preclinical animal models of cancer.

In addition, Zestagen’s mAbs are being assessed against several additional cancer indications, in line with the purported role of hsp90 in facilitating cancer generation and progression.

A snapshot of our pipeline is presented below.

Back to top